Fadi Issa1, Kathryn J Wood. 1. Transplantation Research Immunology Group, Nuffield Department of Surgery, University of Oxford, Oxford, UK.
Abstract
PURPOSE OF REVIEW: Solid organ transplantation is the most effective treatment for end-stage organ failure, but the long-term outcomes remain suboptimal. CD4 regulatory T cells (Tregs) are emerging as a potential therapy to facilitate long-term allograft survival. This review provides a general overview of the biology of CD4 Tregs and then goes on to discuss the most relevant and recent experimental and clinical evidence for their therapeutic use in solid organ transplantation. RECENT FINDINGS: There have been major advances in our understanding of Tregs, including improvements in methods for their isolation and expansion. Experimental models are providing very important data on the in-vitro and in-vivo behavior of Tregs in transplantation, while recent clinical trials of Treg cellular therapy in graft-versus-host disease are offering a valuable insight into the efficacy of Treg adoptive cellular therapy. SUMMARY: Data in favor of Treg cellular therapy in transplantation are mounting, and we predict that their use in clinical trials is on the horizon.
PURPOSE OF REVIEW: Solid organ transplantation is the most effective treatment for end-stage organ failure, but the long-term outcomes remain suboptimal. CD4 regulatory T cells (Tregs) are emerging as a potential therapy to facilitate long-term allograft survival. This review provides a general overview of the biology of CD4 Tregs and then goes on to discuss the most relevant and recent experimental and clinical evidence for their therapeutic use in solid organ transplantation. RECENT FINDINGS: There have been major advances in our understanding of Tregs, including improvements in methods for their isolation and expansion. Experimental models are providing very important data on the in-vitro and in-vivo behavior of Tregs in transplantation, while recent clinical trials of Treg cellular therapy in graft-versus-host disease are offering a valuable insight into the efficacy of Treg adoptive cellular therapy. SUMMARY: Data in favor of Treg cellular therapy in transplantation are mounting, and we predict that their use in clinical trials is on the horizon.
Authors: Emma L Masteller; Matthew R Warner; Qizhi Tang; Kristin V Tarbell; Hugh McDevitt; Jeffrey A Bluestone Journal: J Immunol Date: 2005-09-01 Impact factor: 5.422
Authors: Satish N Nadig; Joanna Wieckiewicz; Douglas C Wu; Gregor Warnecke; Wei Zhang; Shiqiao Luo; Alexandru Schiopu; David P Taggart; Kathryn J Wood Journal: Nat Med Date: 2010-05-16 Impact factor: 53.440
Authors: Gang Feng; Wenda Gao; Terry B Strom; Mohamed Oukka; Ross S Francis; Kathryn J Wood; Andrew Bushell Journal: Eur J Immunol Date: 2008-09 Impact factor: 5.532
Authors: Divya A Verghese; Markus Demir; Nicholas Chun; Miguel Fribourg; Paolo Cravedi; Ines Llaudo; Trent M Woodruff; Pragya Yadav; Sergio A Lira; M Edward Medof; Peter S Heeger Journal: J Immunol Date: 2018-02-07 Impact factor: 5.422
Authors: Bengt Herweg; Madhan Nellaiyappan; Allan M Welter-Frost; Thanh Tran; George Mabry; Kathryn Weston; Catalina Tobón; Javier Saiz; Sami Noujaim; Mark W Weston Journal: Circ Arrhythm Electrophysiol Date: 2021-03-16